Mersana Therapeutics, Inc. (MRSN)
Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN)
29.08
+0.04 (0.14%)
Inactive · Last trade price on Jan 5, 2026

Mersana Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jan '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1451772805854471,823
Market Cap Growth
-42.03%-36.85%-52.15%30.71%-75.46%564.32%
Enterprise Value
9153733322761,569
Last Close Price
29.0835.7558.00146.50155.50665.25
PS Ratio
4.364.367.5922.0010402.132201.35
PB Ratio
--18.587.586.353.677.99
P/TBV Ratio
--7.586.353.677.99
EV/Sales Ratio
2.751.311.9912.486408.321894.81
Debt / Equity Ratio
-0.04-3.010.920.400.320.07
Asset Turnover
0.290.220.130.1000.00
Quick Ratio
1.312.153.293.403.748.50
Current Ratio
1.392.193.363.493.988.62
Return on Equity (ROE)
--505.14%-266.24%-191.03%-97.22%-57.47%
Return on Assets (ROA)
-36.27%-24.73%-38.13%-47.13%-44.02%-28.91%
Return on Invested Capital (ROIC)
--101.99%-107.10%-88.01%-52.05%-33.24%
Return on Capital Employed (ROCE)
-347.00%-89.20%-105.30%-83.90%-106.50%-36.20%
Earnings Yield
-48.20%-39.17%-61.37%-34.93%-38.02%-4.83%
FCF Yield
-51.15%-46.69%-61.14%-8.82%-31.44%-4.12%
Buyback Yield / Dilution
-2.10%-5.54%-23.98%-32.69%-14.79%-41.37%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q